News from The Max Foundation

Am I Doing Enough?

Birthdays are a time to take stock on our life. This birthday, I feel unsettled, questioning if I am doing everything I can.

First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

Armenia and Nepal are the first of 29 countries to receive BRUKINSA SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a...

The Max Foundation Announces Agreement with Lilly to Provide Access to Verzenio® (abemaciclib) for the Treatment of Advanced Breast Cancer in Kenya

Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of...

Targeted Treatment for Advanced Breast Cancer Including CDK4/6 Inhibitor Therapy Reaches Patients in Mozambique for the First Time

Three women diagnosed with HER2- HR+ advanced breast cancer in Mozambique have begun treatment, with efforts underway to open access in eight additional countries  The Max Foundation leading initiative through...

The Max Foundation and International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Partner to Enhance the Care of CLL in Low- and Middle-Income Countries

iwCLL to provide training, medical, and programmatic guidance to support implementation of access program for innovative CLL therapy in 29 LMICs over the next three years SEATTLE, Washington – October...

The Max Foundation welcomes John Menapace as CFO/VP of Administration

We are delighted to announce that John Menapace has joined the Max Foundation as CFO/VP of Administration. John brings demonstrated business leadership to his new role with a background comprising...

The Max Foundation Launches its new patient navigation Program in the United States

The program, Max GPS, will support cancer patients from medically underserved and underrepresented communities. SEATTLE – July 19, 2024 – The Max Foundation (Max), a global nonprofit organization that aims...

The Max Foundation to Launch Treatment Access for Advanced Breast Cancer in Nine Countries Across Africa, Latin America, and South Asia in Q3 2023

The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the...

The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide,...

The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12,...

The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries

Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer The Max Foundation, the...

UICC announces a new global coalition to increase access to and the use of essential cancer medicines in low- and lower middle-income countries

The Union for International Cancer Control (UICC) and multiple partners* are establishing the Access to Oncology Medicines (ATOM) Coalition, a new global partnership to increase access to quality-assured essential cancer...